Definium Therapeutics, Inc. - Common Shares (DFTX) Covered Calls

Definium Therapeutics is a clinical-stage biopharmaceutical company pioneering the development of psychedelic-inspired medicines for brain health. Formerly known as MindMed, the company focuses on delivering scientific rigor to compounds like lysergide to treat Generalized Anxiety Disorder and Major Depressive Disorder. Definium is advancing a robust Phase 3 pipeline aimed at addressing the underlying causes of psychiatric conditions and setting a new standard for mental healthcare.

You can sell covered calls on Definium Therapeutics, Inc. - Common Shares to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for DFTX (prices last updated Fri 4:16 PM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

Definium Therapeutics, Inc. (DFTX), rebranded from MindMed in January 2026, is a leader in the development of next-generation neurotherapeutics. The company’s lead candidate, DT120 ODT (lysergide tartrate), is an orally disintegrating tablet being evaluated for the treatment of Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD). By utilizing a proprietary formulation of lysergide, Definium aims to provide rapid and sustained relief for patients without the significant side-effect profiles associated with traditional SSRIs.

The company’s research strategy is built on the principle of "psychoplastogenics," which involves using molecules that can promote neural plasticity to heal the brain. Definium operates a decentralized clinical trial model and maintains strategic partnerships with academic institutions like NYU Langone and University Hospital Basel. With a robust cash position of over $400 million following a late-2025 equity raise, the company is well-capitalized to fund its clinical milestones through 2028.

Competitive Landscape

Definium operates in the rapidly evolving psychedelic medicine sector, where it competes for clinical talent and intellectual property. Its most direct rival in the public markets is Compass Pathways, which is currently leading the industry with its Phase 3 psilocybin program. The company also tracks against innovative biotech firms in the central nervous system (CNS) space, such as Denali Therapeutics and Biogen.

In the broader mental health market, Definium is benchmarked against established leaders like Johnson & Johnson, whose esketamine-based Spravato has successfully paved the regulatory and commercial path for office-based psychiatric treatments. Definium’s competitive moat is protected by an extensive patent portfolio covering its ODT technology and specific dosing regimens, as well as its FDA Breakthrough Therapy Designation for GAD.

Strategic Outlook and Innovation

The strategic outlook for Definium in 2026 is defined by a series of pivotal Phase 3 readouts. Top-line data for "Emerge" (MDD) is anticipated in late Q2 2026, followed closely by the "Voyage" study (GAD) in early Q3. Management is currently preparing for a potential New Drug Application (NDA) submission, leveraging its breakthrough status to maintain a high level of engagement with the FDA regarding trial endpoints and commercial safety protocols.

Beyond its late-stage psychiatric programs, Definium is innovating through its DT402 program, which began Phase 2a trials for Autism Spectrum Disorder (ASD) in early 2026. The company is also exploring the use of digital medicine tools to monitor patient outcomes in real-time, providing a more objective dataset for therapeutic efficacy. These innovations are part of Definium’s broader mission to transition from a research biotech into a commercially viable provider of precision psychiatry.

Want more examples? DFJ Covered Calls | DG Covered Calls